Idecabtagene vicleucel versus standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma: KarMMa-3, a phase 3 randomized controlled trial Meeting Abstract
| Authors: | Rodríguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; Bahlis, N. J.; Moreau, P.; Solomon, S. R.; Delforge, M.; Berdeja, J.; Truppel-Hartmann, A.; Yang, Z.; Favre-Kontula, L.; Wu, F.; Piasecki, J.; Cook, M.; Giralt, S. |
| Abstract Title: | Idecabtagene vicleucel versus standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma: KarMMa-3, a phase 3 randomized controlled trial |
| Meeting Title: | 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) |
| Journal Title: | Bone Marrow Transplantation |
| Volume: | 58 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Apr 23-26 |
| Meeting Location: | Paris, France |
| ISSN: | 0268-3369 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2023-12-01 |
| Start Page: | 17 |
| End Page: | 18 |
| Language: | English |
| ACCESSION: | WOS:001110902800007 |
| PROVIDER: | wos |
| PUBMED: | 37945719 |
| DOI: | 10.1038/s41409-023-02054-9 |
| Notes: | Meeting Abstract: O006 -- Found in section, "Physicians Award Winners" -- This was a hybrid meeting -- Source: Wos |
